ATRA Atara Biotherapeutics | $11.40
+14.8% | 12/20/2024 | Initiated by | Rodman & Renshaw | - | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024 |
HURA TuHURA Biosciences | $4.48
+12.0% | 12/19/2024 | Initiated by | Rodman & Renshaw | - | Buy | $11.00 | N/A | View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024 |
FBLG FibroBiologics | $2.25
+10.8% | 12/12/2024 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of FibroBiologics (NASDAQ:FBLG) on 12/12/2024 |
RMTI Rockwell Medical | $2.08
+1.5% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024 |
OMER Omeros | $10.31
+0.7% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024 |
EPRX Eupraxia Pharmaceuticals | $2.99
-0.3% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024 |
|
ACHV Achieve Life Sciences | $3.69
-3.4% | 11/14/2024 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024 |
BCAX Bicara Therapeutics | $17.59
+6.0% | 11/5/2024 | Initiated by | Rodman & Renshaw | - | Buy | $48.00 | Low | View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024 |
QNCX Quince Therapeutics | $1.78
+1.1% | 10/29/2024 | Initiated by | Rodman & Renshaw | - | Buy | $11.00 | Medium | View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024 |
ANRO Alto Neuroscience | $3.89
+4.6% | 10/23/2024 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | High | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024 |
MNPR Monopar Therapeutics | $25.82
+8.5% | 10/11/2024 | Initiated by | Rodman & Renshaw | - | Buy | $50.00 | High | View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024 |
NKTX Nkarta | $2.37
+7.7% | 10/9/2024 | Initiated by | Rodman & Renshaw | - | Buy | $14.00 | Medium | View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024 |
KYTX Kyverna Therapeutics | $4.00
+3.4% | 10/9/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | High | View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024 |
MIRA MIRA Pharmaceuticals | $1.06
+6.0% | 9/30/2024 | Initiated by | Rodman & Renshaw | - | Buy | $17.00 | High | View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024 |
BMEA Biomea Fusion | $4.23
+3.7% | 9/26/2024 | Upgraded by | Rodman & Renshaw | - | Neutral -> Buy | $18.00 | Medium | View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024 |
EBS Emergent BioSolutions | $8.10
+0.5% | 9/13/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $16.00 -> $16.00 | Low | View details for Rodman & Renshaw rating of Emergent BioSolutions (NYSE:EBS) on 9/13/2024 |
ATHA Athira Pharma | $0.58
+5.1% | 9/4/2024 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | Low | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 9/4/2024 |
PASG Passage Bio | $0.66
+0.9% | 9/3/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024 |
CRMD CorMedix | $8.57
-3.4% | 8/26/2024 | Initiated by | Rodman & Renshaw | - | Buy | $13.00 | Low | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024 |
UBX Unity Biotechnology | $0.96
-1.0% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of Unity Biotechnology (NASDAQ:UBX) on 8/22/2024 |
MIST Milestone Pharmaceuticals | $1.80
+5.0% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | Low | View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024 |
DERM Journey Medical | $4.68
+0.6% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | Low | View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024 |
EBS Emergent BioSolutions | $8.10
+0.5% | 8/22/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | Low | View details for Rodman & Renshaw rating of Emergent BioSolutions (NYSE:EBS) on 8/22/2024 |
ATHA Athira Pharma | $0.58
+5.1% | 8/19/2024 | Initiated by | Rodman & Renshaw | - | Buy | $22.00 | Low | View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 8/19/2024 |
SAVA Cassava Sciences | $2.35
+2.6% | 8/8/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $107.00 -> $107.00 | Low | View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:SAVA) on 8/8/2024 |
IPSC Century Therapeutics | $1.10
+4.8% | 8/8/2024 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | Low | View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024 |
CRSP CRISPR Therapeutics | $40.72
+0.8% | 8/2/2024 | Initiated by | Rodman & Renshaw | - | Buy | $90.00 | Low | View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024 |
ANVS Annovis Bio | $4.37
-0.7% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $67.00 -> $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024 |
CGTX Cognition Therapeutics | $0.63
-0.6% | 7/2/2024 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $14.00 -> $14.00 | Low | View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024 |
NKTR Nektar Therapeutics | $0.93
-1.3% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $2.00 | Low | View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024 |
LPTX Leap Therapeutics | $2.91
+4.7% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of Leap Therapeutics (NASDAQ:LPTX) on 6/28/2024 |
MURA Mural Oncology | $3.18
+1.3% | 6/28/2024 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | Low | View details for Rodman & Renshaw rating of Mural Oncology (NASDAQ:MURA) on 6/28/2024 |
SANA Sana Biotechnology | $1.65
+3.1% | 6/26/2024 | Initiated by | Rodman & Renshaw | - | Buy | $16.00 | Low | View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024 |
ANRO Alto Neuroscience | $3.89
+4.6% | 6/21/2024 | Initiated by | Rodman & Renshaw | - | Buy | $43.00 | Low | View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024 |
COYA Coya Therapeutics | $5.24
+1.6% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | Low | View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024 |
TRVI Trevi Therapeutics | $4.05
-2.4% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024 |
SCLX Scilex | $0.45
+1.6% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $13.00 | Low | View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024 |
RANI Rani Therapeutics | $1.40
+7.7% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | Low | View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024 |
MNKD MannKind | $6.85
+8.7% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | Low | View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024 |
HRTX Heron Therapeutics | $1.58
+3.3% | 6/13/2024 | Initiated by | Rodman & Renshaw | - | Buy | $7.00 | Low | View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024 |
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now |
AVDL Avadel Pharmaceuticals | $10.31
+2.0% | 6/12/2024 | Initiated by | Rodman & Renshaw | - | Buy | $27.00 | Low | View details for Rodman & Renshaw rating of Avadel Pharmaceuticals (NASDAQ:AVDL) on 6/12/2024 |
ANVS Annovis Bio | $4.37
-0.7% | 6/4/2024 | Initiated by | Rodman & Renshaw | - | Buy | $67.00 | Low | View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024 |
BHC Bausch Health Companies | $7.47
+1.1% | 8/10/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | High | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 8/10/2017 |
CRMD CorMedix | $8.57
-3.4% | 8/10/2017 | Target Lowered by | Rodman & Renshaw | - | Buy -> Buy | $25.00 -> $15.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017 |
GEVO Gevo | $1.52
+4.1% | 8/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $240.00 | Medium | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017 |
POETF POET Technologies | $4.81
-0.4% | 8/7/2017 | Initiated by | Rodman & Renshaw | - | Buy | | High | View details for Rodman & Renshaw rating of POET Technologies (OTCMKTS:POETF) on 8/7/2017 |
VERU Veru | $0.65
+3.3% | 7/26/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | High | View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017 |
PLUG Plug Power | $2.56
+11.3% | 7/24/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | Low | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017 |
CAPR Capricor Therapeutics | $13.07
+1.3% | 7/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.15 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017 |
BYSI BeyondSpring | $1.59
+2.6% | 7/14/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $43.00 -> $50.00 | Medium | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017 |
JAGX Jaguar Health | $0.93
+6.0% | 7/11/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $360.00 | High | View details for Rodman & Renshaw rating of Jaguar Health (NASDAQ:JAGX) on 7/11/2017 |
FBIO Fortress Biotech | $1.72
-1.1% | 7/11/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $165.00 | Low | View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017 |
AQMS Aqua Metals | $1.92
+9.7% | 7/2/2017 | Initiated by | Rodman & Renshaw | - | Buy | $500.00 -> $500.00 | Low | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 7/2/2017 |
EMAN eMagin | $2.07
| 6/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $4.00 | N/A | View details for Rodman & Renshaw rating of eMagin (NYSEAMERICAN:EMAN) on 6/23/2017 |
AQMS Aqua Metals | $1.92
+9.7% | 6/22/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $500.00 | Low | View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 6/22/2017 |
USA Americas Silver | C$0.57
+5.6% | 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy | C$4.00 | N/A | View details for Rodman & Renshaw rating of Americas Silver (TSE:USA) on 6/15/2017 |
USAS Americas Silver | $0.44
+18.8% | 6/15/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $4.00 -> $4.00 | Medium | View details for Rodman & Renshaw rating of Americas Silver (NYSEAMERICAN:USAS) on 6/15/2017 |
APTO Aptose Biosciences | $0.28
+63.9% | 6/8/2017 | Initiated by | Rodman & Renshaw | - | Neutral -> Neutral | | High | View details for Rodman & Renshaw rating of Aptose Biosciences (NASDAQ:APTO) on 6/8/2017 |
EYPT EyePoint Pharmaceuticals | $7.10
-0.3% | 5/30/2017 | Initiated by | Rodman & Renshaw | - | Buy | $800.00 | High | View details for Rodman & Renshaw rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 5/30/2017 |
PIRS Pieris Pharmaceuticals | $13.60
-15.7% | 5/30/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $720.00 | High | View details for Rodman & Renshaw rating of Pieris Pharmaceuticals (NASDAQ:PIRS) on 5/30/2017 |
PLX Protalix BioTherapeutics | $1.76
+1.1% | 5/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 5/23/2017 |
ACAD ACADIA Pharmaceuticals | $16.87
+0.8% | 5/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $60.00 | Low | View details for Rodman & Renshaw rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) on 5/22/2017 |
BHC Bausch Health Companies | $7.47
+1.1% | 5/19/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $17.00 | Medium | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 5/19/2017 |
MGIC Magic Software Enterprises | $12.04
+1.2% | 5/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $9.00 -> $10.00 | Medium | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 5/17/2017 |
SSKN STRATA Skin Sciences | $2.89
-5.2% | 5/16/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $15.00 -> $120.00 | High | View details for Rodman & Renshaw rating of STRATA Skin Sciences (NASDAQ:SSKN) on 5/16/2017 |
IOVA Iovance Biotherapeutics | $7.38
+2.2% | 5/10/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $13.00 | Low | View details for Rodman & Renshaw rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/10/2017 |
CRMD CorMedix | $8.57
-3.4% | 5/5/2017 | Target Lowered by | Rodman & Renshaw | - | Buy | $30.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 5/5/2017 |
AMSC American Superconductor | $25.15
+4.2% | 4/28/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $10.00 -> $7.50 | High | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/28/2017 |
GOLD Barrick Gold | $15.46
+1.5% | 4/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $4.25 -> $4.50 | N/A | View details for Rodman & Renshaw rating of Barrick Gold (NYSE:GOLD) on 4/24/2017 |
PLX Protalix BioTherapeutics | $1.76
+1.1% | 4/17/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
PLX Protalix BioTherapeutics | $1.76
+1.1% | 4/17/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $40.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/17/2017 |
WRN Western Copper and Gold | C$1.49
+2.1% | 4/10/2017 | Reiterated by | Rodman & Renshaw | - | Buy | C$2.00 | N/A | View details for Rodman & Renshaw rating of Western Copper and Gold (TSE:WRN) on 4/10/2017 |
WRN Western Copper and Gold | $1.04
+3.0% | 4/7/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $2.00 | Medium | View details for Rodman & Renshaw rating of Western Copper and Gold (NYSEAMERICAN:WRN) on 4/7/2017 |
PLUG Plug Power | $2.56
+11.3% | 4/6/2017 | Target Raised by | Rodman & Renshaw | - | Buy -> Buy | $3.00 -> $4.00 | High | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 4/6/2017 |
BYSI BeyondSpring | $1.59
+2.6% | 4/4/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $43.00 | Low | View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 4/4/2017 |
CYTK Cytokinetics | $48.87
+4.6% | 3/23/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | Medium | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/23/2017 |
HROW Harrow | $34.22
-0.6% | 3/22/2017 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 | High | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 3/22/2017 |
MAG MAG Silver | $13.83
-0.3% | 3/9/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $20.00 -> $20.50 | Low | View details for Rodman & Renshaw rating of MAG Silver (NYSEAMERICAN:MAG) on 3/9/2017 |
CYTK Cytokinetics | $48.87
+4.6% | 3/8/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $25.00 | High | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 3/8/2017 |
BHC Bausch Health Companies | $7.47
+1.1% | 3/6/2017 | Target Lowered by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/6/2017 |
MGIC Magic Software Enterprises | $12.04
+1.2% | 3/6/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $8.00 -> $9.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 3/6/2017 |
QRHC Quest Resource | $6.00
+0.5% | 3/6/2017 | Initiated by | Rodman & Renshaw | - | Buy -> Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Quest Resource (NASDAQ:QRHC) on 3/6/2017 |
BHC Bausch Health Companies | $7.47
+1.1% | 2/27/2017 | Reiterated by | Rodman & Renshaw | - | Neutral | $23.00 -> $17.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/27/2017 |
SSKN STRATA Skin Sciences | $2.89
-5.2% | 2/21/2017 | Reiterated by | Rodman & Renshaw | - | Buy -> Buy | $15.00 | N/A | View details for Rodman & Renshaw rating of STRATA Skin Sciences (NASDAQ:SSKN) on 2/21/2017 |
CAPR Capricor Therapeutics | $13.07
+1.3% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $14.00 | N/A | View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 2/13/2017 |
BLRX BioLineRx | $0.20
+0.5% | 2/13/2017 | Initiated by | Rodman & Renshaw | - | Buy | $3.00 | N/A | View details for Rodman & Renshaw rating of BioLineRx (NASDAQ:BLRX) on 2/13/2017 |
ABEO Abeona Therapeutics | $5.70
+1.2% | 2/7/2017 | Reiterated by | Rodman & Renshaw | Analyst ram selvaraju | Buy | $425.00 -> $500.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 2/7/2017 |
BHC Bausch Health Companies | $7.47
+1.1% | 1/31/2017 | Downgraded by | Rodman & Renshaw | - | Buy -> Neutral | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 1/31/2017 |
ASM Avino Silver & Gold Mines | $0.89
-2.7% | 1/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $3.50 -> $4.00 | N/A | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
ASM Avino Silver & Gold Mines | $0.93
+4.9% | 1/24/2017 | Target Raised by | Rodman & Renshaw | - | Buy | $3.50 -> $4.00 | N/A | View details for Rodman & Renshaw rating of Avino Silver & Gold Mines (NYSE:ASM) on 1/24/2017 |
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now |
CDXC ChromaDex | $5.49
+1.5% | 1/3/2017 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of ChromaDex (NASDAQ:CDXC) on 1/3/2017 |
PLUG Plug Power | $2.56
+11.3% | 12/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $3.00 | N/A | View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 12/6/2016 |
GOLD Barrick Gold | $15.46
+1.5% | 11/28/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $4.00 -> $4.25 | N/A | View details for Rodman & Renshaw rating of Barrick Gold (NYSE:GOLD) on 11/28/2016 |
HROW Harrow | $34.22
-0.6% | 11/28/2016 | Initiated by | Rodman & Renshaw | - | Buy | $5.00 | N/A | View details for Rodman & Renshaw rating of Harrow (NASDAQ:HROW) on 11/28/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 11/10/2016 | Downgraded by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy -> Neutral | $81.00 -> $23.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 11/10/2016 |
GGD GoGold Resources | C$1.10
+2.8% | 10/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | C$3.50 -> C$3.00 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 10/7/2016 |
CYDY CytoDyn | $0.12
-3.3% | 10/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $1.60 | N/A | View details for Rodman & Renshaw rating of CytoDyn (OTCMKTS:CYDY) on 10/6/2016 |
TGEN Tecogen | $1.59
-0.1% | 10/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of Tecogen (OTCMKTS:TGEN) on 10/4/2016 |
DRRX DURECT | $0.95
+10.7% | 9/27/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 -> $35.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 9/27/2016 |
CLNE Clean Energy Fuels | $2.56
+1.2% | 9/23/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Clean Energy Fuels (NASDAQ:CLNE) on 9/23/2016 |
UUUU Energy Fuels | $5.30
-2.0% | 9/22/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $5.00 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 9/22/2016 |
UUUU Energy Fuels | $5.30
-2.0% | 9/22/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.30 -> $5.00 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 9/22/2016 |
VNRX VolitionRx | $0.68
+16.3% | 9/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 9/7/2016 |
VNRX VolitionRx | $0.68
+16.3% | 9/7/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 9/7/2016 |
MEEC Midwest Energy Emissions | $0.54
-1.3% | 9/7/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Midwest Energy Emissions (OTCMKTS:MEEC) on 9/7/2016 |
HL Hecla Mining | $5.04
+1.8% | 9/6/2016 | Initiated by | Rodman & Renshaw | - | Buy | $9.00 | N/A | View details for Rodman & Renshaw rating of Hecla Mining (NYSE:HL) on 9/6/2016 |
REI Ring Energy | $1.25
| 8/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $15.00 | N/A | View details for Rodman & Renshaw rating of Ring Energy (NYSEAMERICAN:REI) on 8/29/2016 |
DRIO DarioHealth | $0.80
+8.1% | 8/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 8/22/2016 |
ORMP Oramed Pharmaceuticals | $2.37
-4.8% | 8/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 8/21/2016 |
ABEO Abeona Therapeutics | $5.70
+1.2% | 8/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/21/2016 |
SMT Sierra Metals | C$0.84
-2.3% | 8/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | C$3.00 | N/A | View details for Rodman & Renshaw rating of Sierra Metals (TSE:SMT) on 8/18/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 8/9/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 -> $81.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 8/9/2016 |
ABEO Abeona Therapeutics | $5.70
+1.2% | 8/5/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 8/5/2016 |
DRRX DURECT | $0.95
+10.7% | 8/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 8/3/2016 |
EKSO Ekso Bionics | $0.58
-10.2% | 7/31/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 7/31/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 7/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/28/2016 |
KURA Kura Oncology | $9.01
+0.4% | 7/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 7/18/2016 |
F Ford Motor | $9.88
+1.4% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ford Motor (NYSE:F) on 7/18/2016 |
OESX Orion Energy Systems | $0.84
+3.7% | 7/18/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Orion Energy Systems (NASDAQ:OESX) on 7/18/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 7/17/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/17/2016 |
PLX Protalix BioTherapeutics | $1.76
+1.1% | 7/11/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 7/11/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $90.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 7/6/2016 |
DRRX DURECT | $0.95
+10.7% | 7/6/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 7/6/2016 |
INO Inovio Pharmaceuticals | $1.84
-0.3% | 6/21/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $2,448.00 | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 6/21/2016 |
WPRT Westport Fuel Systems | $3.38
-2.0% | 6/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $50.00 | N/A | View details for Rodman & Renshaw rating of Westport Fuel Systems (NASDAQ:WPRT) on 6/20/2016 |
VNRX VolitionRx | $0.68
+16.3% | 6/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 6/16/2016 |
KURA Kura Oncology | $9.01
+0.4% | 5/24/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 5/24/2016 |
DRIO DarioHealth | $0.80
+8.1% | 5/24/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/24/2016 |
ABEO Abeona Therapeutics | $5.70
+1.2% | 5/18/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 5/18/2016 |
VNRX VolitionRx | $0.68
+16.3% | 5/16/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 5/16/2016 |
DRRX DURECT | $0.95
+10.7% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 5/13/2016 |
ORMP Oramed Pharmaceuticals | $2.37
-4.8% | 5/13/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 5/13/2016 |
MBOT Microbot Medical | $0.97
-0.4% | 5/10/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 5/10/2016 |
DRIO DarioHealth | $0.80
+8.1% | 5/9/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of DarioHealth (NASDAQ:DRIO) on 5/9/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 5/3/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 -> $102.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 5/3/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 4/26/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/26/2016 |
DRRX DURECT | $0.95
+10.7% | 4/25/2016 | Initiated by | Rodman & Renshaw | - | Buy | $40.00 | N/A | View details for Rodman & Renshaw rating of DURECT (NASDAQ:DRRX) on 4/25/2016 |
VNRX VolitionRx | $0.68
+16.3% | 4/21/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 4/21/2016 |
ABEO Abeona Therapeutics | $5.70
+1.2% | 4/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $425.00 | N/A | View details for Rodman & Renshaw rating of Abeona Therapeutics (NASDAQ:ABEO) on 4/20/2016 |
MBOT Microbot Medical | $0.97
-0.4% | 4/20/2016 | Initiated by | Rodman & Renshaw | - | Buy | $18.00 | N/A | View details for Rodman & Renshaw rating of Microbot Medical (NASDAQ:MBOT) on 4/20/2016 |
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now |
AG First Majestic Silver | $5.46
+0.2% | 4/15/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $6.00 -> $8.75 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 4/15/2016 |
SMLR Semler Scientific | $61.78
+0.7% | 4/15/2016 | Initiated by | Rodman & Renshaw | - | Buy | $8.00 | N/A | View details for Rodman & Renshaw rating of Semler Scientific (NASDAQ:SMLR) on 4/15/2016 |
EXK Endeavour Silver | $3.71
+1.6% | 4/12/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.50 -> $3.40 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 4/12/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 4/11/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 -> $105.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/11/2016 |
INO Inovio Pharmaceuticals | $1.84
-0.3% | 4/9/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 4/9/2016 |
VNRX VolitionRx | $0.68
+16.3% | 4/9/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 4/9/2016 |
EKSO Ekso Bionics | $0.58
-10.2% | 4/5/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $21.00 | N/A | View details for Rodman & Renshaw rating of Ekso Bionics (NASDAQ:EKSO) on 4/5/2016 |
KURA Kura Oncology | $9.01
+0.4% | 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $52,500.00 | N/A | View details for Rodman & Renshaw rating of Kura Oncology (NASDAQ:KURA) on 4/4/2016 |
PLX Protalix BioTherapeutics | $1.76
+1.1% | 4/4/2016 | Initiated by | Rodman & Renshaw | - | Buy | $35.00 | N/A | View details for Rodman & Renshaw rating of Protalix BioTherapeutics (NYSE:PLX) on 4/4/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 4/3/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 4/3/2016 |
AMSC American Superconductor | $25.15
+4.2% | 4/1/2016 | Reiterated by | Rodman & Renshaw | Analyst Amit Dayal | Neutral | | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 4/1/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 3/28/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/28/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 3/22/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/22/2016 |
NNDM Nano Dimension | $2.49
| 3/21/2016 | Initiated by | Rodman & Renshaw | - | Buy | $700.00 | N/A | View details for Rodman & Renshaw rating of Nano Dimension (NASDAQ:NNDM) on 3/21/2016 |
INO Inovio Pharmaceuticals | $1.84
-0.3% | 3/20/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 3/20/2016 |
UUUU Energy Fuels | $5.30
-2.0% | 3/17/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $6.90 -> $6.30 | N/A | View details for Rodman & Renshaw rating of Energy Fuels (NYSE:UUUU) on 3/17/2016 |
CRMD CorMedix | $8.57
-3.4% | 3/17/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $32.50 -> $37.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 3/17/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 3/16/2016 | Target Lowered by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 -> $118.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/16/2016 |
MUX McEwen Mining | $7.98
+1.7% | 3/14/2016 | Target Raised by | Rodman & Renshaw | - | | $13.00 -> $24.00 | N/A | View details for Rodman & Renshaw rating of McEwen Mining (NYSE:MUX) on 3/14/2016 |
VNRX VolitionRx | $0.68
+16.3% | 3/14/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 3/14/2016 |
INSG Inseego | $10.81
-0.6% | 3/7/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $60.00 -> $30.00 | N/A | View details for Rodman & Renshaw rating of Inseego (NASDAQ:INSG) on 3/7/2016 |
PLM PolyMet Mining | $2.10
-0.5% | 3/4/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $2.00 -> $2.40 | N/A | View details for Rodman & Renshaw rating of PolyMet Mining (NYSEAMERICAN:PLM) on 3/4/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 3/2/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 3/2/2016 |
AG First Majestic Silver | $5.46
+0.2% | 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $6.00 | N/A | View details for Rodman & Renshaw rating of First Majestic Silver (NYSE:AG) on 2/29/2016 |
EXK Endeavour Silver | $3.71
+1.6% | 2/29/2016 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Endeavour Silver (NYSE:EXK) on 2/29/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 2/23/2016 | Reiterated by | Rodman & Renshaw | Analyst Ram Selvaraju | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/23/2016 |
RDCM RADCOM | $11.89
+2.5% | 2/18/2016 | Target Raised by | Rodman & Renshaw | - | Buy | $12.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of RADCOM (NASDAQ:RDCM) on 2/18/2016 |
BHC Bausch Health Companies | $7.47
+1.1% | 2/16/2016 | Initiated by | Rodman & Renshaw | - | Buy | $150.00 | N/A | View details for Rodman & Renshaw rating of Bausch Health Companies (NYSE:BHC) on 2/16/2016 |
TMQ Trilogy Metals | $1.10
+1.9% | 2/11/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/11/2016 |
TMQ Trilogy Metals | $1.10
+1.9% | 2/10/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $1.40 -> $1.30 | N/A | View details for Rodman & Renshaw rating of Trilogy Metals (NYSEAMERICAN:TMQ) on 2/10/2016 |
BCRX BioCryst Pharmaceuticals | $7.57
+2.4% | 2/9/2016 | Target Lowered by | Rodman & Renshaw | - | Buy | $24.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) on 2/9/2016 |
VNRX VolitionRx | $0.68
+16.3% | 2/1/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of VolitionRx (NYSEAMERICAN:VNRX) on 2/1/2016 |
INO Inovio Pharmaceuticals | $1.84
-0.3% | 1/29/2016 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Inovio Pharmaceuticals (NASDAQ:INO) on 1/29/2016 |
IPWR Ideal Power | $6.83
+7.2% | 1/26/2016 | Initiated by | Rodman & Renshaw | - | Buy | $12.00 | N/A | View details for Rodman & Renshaw rating of Ideal Power (NASDAQ:IPWR) on 1/26/2016 |
AMSC American Superconductor | $25.15
+4.2% | 1/13/2016 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of American Superconductor (NASDAQ:AMSC) on 1/13/2016 |
ORMP Oramed Pharmaceuticals | $2.37
-4.8% | 1/10/2016 | Reiterated by | Rodman & Renshaw | - | Buy | $25.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 1/10/2016 |
GGD GoGold Resources | C$1.10
+2.8% | 12/21/2015 | Target Raised by | Rodman & Renshaw | - | | C$2.70 -> C$2.90 | N/A | View details for Rodman & Renshaw rating of GoGold Resources (TSE:GGD) on 12/21/2015 |
MVIS MicroVision | $0.99
+3.9% | 12/17/2015 | Initiated by | Rodman & Renshaw | - | Buy | $3.50 | N/A | View details for Rodman & Renshaw rating of MicroVision (NASDAQ:MVIS) on 12/17/2015 |
CRMD CorMedix | $8.57
-3.4% | 12/16/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 12/16/2015 |
VUZI Vuzix | $4.40
+18.3% | 12/10/2015 | Initiated by | Rodman & Renshaw | - | Buy | $10.00 | N/A | View details for Rodman & Renshaw rating of Vuzix (NASDAQ:VUZI) on 12/10/2015 |
CRMD CorMedix | $8.57
-3.4% | 11/12/2015 | Initiated by | Rodman & Renshaw | - | Buy | $32.50 | N/A | View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 11/12/2015 |
BLDP Ballard Power Systems | $1.62
+8.0% | 10/5/2015 | Reiterated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 10/5/2015 |
ORMP Oramed Pharmaceuticals | $2.37
-4.8% | 10/1/2015 | Initiated by | Rodman & Renshaw | - | Buy | $24.00 | N/A | View details for Rodman & Renshaw rating of Oramed Pharmaceuticals (NASDAQ:ORMP) on 10/1/2015 |
BLDP Ballard Power Systems | $1.62
+8.0% | 8/20/2015 | Initiated by | Rodman & Renshaw | - | Buy | $2.50 | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 8/20/2015 |
GEVO Gevo | $1.52
+4.1% | 8/19/2015 | Initiated by | Rodman & Renshaw | - | Buy | $100.00 | N/A | View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/19/2015 |
BLDP Ballard Power Systems | $1.62
+8.0% | 7/14/2015 | Initiated by | Rodman & Renshaw | - | Buy | | N/A | View details for Rodman & Renshaw rating of Ballard Power Systems (NASDAQ:BLDP) on 7/14/2015 |
CPRX Catalyst Pharmaceuticals | $21.27
-0.9% | 8/27/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $3.70 | N/A | View details for Rodman & Renshaw rating of Catalyst Pharmaceuticals (NASDAQ:CPRX) on 8/27/2012 |
CYTK Cytokinetics | $48.87
+4.6% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $2.00 | N/A | View details for Rodman & Renshaw rating of Cytokinetics (NASDAQ:CYTK) on 7/31/2012 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 7/31/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $22.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/31/2012 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 7/27/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $38.00 -> $39.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 7/27/2012 |
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad) Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days.
It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year.
This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now |
AMGN Amgen | $263.38
+0.8% | 7/23/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $73.00 -> $89.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 7/23/2012 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 7/16/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 7/16/2012 |
ALGT Allegiant Travel | $84.47
+2.9% | 7/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $72.00 -> $79.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 7/13/2012 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 7/5/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $38.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 7/5/2012 |
ASMB Assembly Biosciences | $15.21
-3.8% | 6/26/2012 | Target Lowered by | Rodman & Renshaw | - | | $132.00 | N/A | View details for Rodman & Renshaw rating of Assembly Biosciences (NASDAQ:ASMB) on 6/26/2012 |
RPMT Rego Payment Architectures | $0.96
-0.1% | 6/25/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $5.00 | N/A | View details for Rodman & Renshaw rating of Rego Payment Architectures (OTCMKTS:RPMT) on 6/25/2012 |
AMGN Amgen | $263.38
+0.8% | 6/21/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $57.00 -> $73.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 6/21/2012 |
MNOV MediciNova | $2.17
+0.5% | 6/19/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of MediciNova (NASDAQ:MNOV) on 6/19/2012 |
DCO Ducommun | $61.89
+1.1% | 5/24/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Ducommun (NYSE:DCO) on 5/24/2012 |
POWL Powell Industries | $245.80
+1.0% | 5/10/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $43.00 | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 5/10/2012 |
NPO Enpro | $173.22
-1.2% | 5/4/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $47.00 -> $50.00 | N/A | View details for Rodman & Renshaw rating of Enpro (NYSE:NPO) on 5/4/2012 |
RMTI Rockwell Medical | $2.08
+1.5% | 4/24/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $176.00 | N/A | View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 4/24/2012 |
SYK Stryker | $364.60
+2.1% | 4/20/2012 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Stryker (NYSE:SYK) on 4/20/2012 |
PODD Insulet | $266.57
+3.9% | 4/18/2012 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | | N/A | View details for Rodman & Renshaw rating of Insulet (NASDAQ:PODD) on 4/18/2012 |
B Barnes Group | $47.16
+0.1% | 4/3/2012 | Initiated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Barnes Group (NYSE:B) on 4/3/2012 |
TRS TriMas | $24.52
-0.8% | 3/15/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $32.00 | N/A | View details for Rodman & Renshaw rating of TriMas (NASDAQ:TRS) on 3/15/2012 |
OMER Omeros | $10.31
+0.7% | 3/13/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $13.00 -> $16.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 3/13/2012 |
AMGN Amgen | $263.38
+0.8% | 3/7/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 3/7/2012 |
VSTM Verastem | $4.19
-5.6% | 3/7/2012 | Initiated by | Rodman & Renshaw | - | Buy -> Market Perform | | N/A | View details for Rodman & Renshaw rating of Verastem (NASDAQ:VSTM) on 3/7/2012 |
ANIP ANI Pharmaceuticals | $53.35
-1.7% | 2/27/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 2/27/2012 |
MNTX Manitex International | $5.72
-0.2% | 2/23/2012 | Target Raised by | Rodman & Renshaw | - | | $10.00 | N/A | View details for Rodman & Renshaw rating of Manitex International (NASDAQ:MNTX) on 2/23/2012 |
MDGL Madrigal Pharmaceuticals | $308.44
+5.1% | 2/22/2012 | Reiterated by | Rodman & Renshaw | - | Market Perform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 2/22/2012 |
MGIC Magic Software Enterprises | $12.04
+1.2% | 2/15/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $8.00 -> $10.00 | N/A | View details for Rodman & Renshaw rating of Magic Software Enterprises (NASDAQ:MGIC) on 2/15/2012 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 2/6/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $19.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/6/2012 |
DAL Delta Air Lines | $60.93
+0.9% | 2/6/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $14.00 | N/A | View details for Rodman & Renshaw rating of Delta Air Lines (NYSE:DAL) on 2/6/2012 |
ALGT Allegiant Travel | $84.47
+2.9% | 2/2/2012 | Target Raised by | Rodman & Renshaw | - | | $62.00 | N/A | View details for Rodman & Renshaw rating of Allegiant Travel (NASDAQ:ALGT) on 2/2/2012 |
POWL Powell Industries | $245.80
+1.0% | 1/26/2012 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Powell Industries (NASDAQ:POWL) on 1/26/2012 |
SILC Silicom | $15.13
+1.2% | 1/24/2012 | Target Raised by | Rodman & Renshaw | - | Outperform | $20.00 -> $25.00 | N/A | View details for Rodman & Renshaw rating of Silicom (NASDAQ:SILC) on 1/24/2012 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 1/23/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 1/23/2012 |
LUV Southwest Airlines | $33.28
+1.5% | 1/20/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 1/20/2012 |
AMGN Amgen | $263.38
+0.8% | 1/17/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 1/17/2012 |
MDGL Madrigal Pharmaceuticals | $308.44
+5.1% | 1/5/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $8.00 | N/A | View details for Rodman & Renshaw rating of Madrigal Pharmaceuticals (NASDAQ:MDGL) on 1/5/2012 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 1/4/2012 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 1/4/2012 |
WWD Woodward | $168.70
+0.3% | 1/4/2012 | Initiated by | Rodman & Renshaw | - | Outperform | $52.00 | N/A | View details for Rodman & Renshaw rating of Woodward (NASDAQ:WWD) on 1/4/2012 |
AMGN Amgen | $263.38
+0.8% | 12/23/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $57.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/23/2011 |
ANIP ANI Pharmaceuticals | $53.35
-1.7% | 12/15/2011 | Downgraded by | Rodman & Renshaw | - | Outperform -> Market Perform | | N/A | View details for Rodman & Renshaw rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 12/15/2011 |
INTC Intel | $19.52
+2.4% | 12/13/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $27.00 | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 12/13/2011 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 12/13/2011 | Target Lowered by | Rodman & Renshaw | - | | $51.00 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 12/13/2011 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/12/2011 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 12/12/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 12/12/2011 |
OMER Omeros | $10.31
+0.7% | 12/5/2011 | Upgraded by | Rodman & Renshaw | - | Market Perform -> Outperform | $13.00 | N/A | View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 12/5/2011 |
ROG Rogers | $99.95
-1.5% | 12/2/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $55.00 | N/A | View details for Rodman & Renshaw rating of Rogers (NYSE:ROG) on 12/2/2011 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 12/1/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 12/1/2011 |
AMGN Amgen | $263.38
+0.8% | 12/1/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $62.00 | N/A | View details for Rodman & Renshaw rating of Amgen (NASDAQ:AMGN) on 12/1/2011 |
CRIS Curis | $3.08
+0.3% | 11/30/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/30/2011 |
EW Edwards Lifesciences | $74.81
+1.2% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/29/2011 |
AAPL Apple | $254.49
+1.9% | 11/29/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $16.07 | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/29/2011 |
LUV Southwest Airlines | $33.28
+1.5% | 11/21/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $12.00 | N/A | View details for Rodman & Renshaw rating of Southwest Airlines (NYSE:LUV) on 11/21/2011 |
DELL Dell Technologies | $115.77
+3.4% | 11/15/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $18.00 | N/A | View details for Rodman & Renshaw rating of Dell Technologies (NYSE:DELL) on 11/15/2011 |
MNTX Manitex International | $5.72
-0.2% | 11/15/2011 | Initiated by | Rodman & Renshaw | - | Outperform | $6.50 | N/A | View details for Rodman & Renshaw rating of Manitex International (NASDAQ:MNTX) on 11/15/2011 |
EW Edwards Lifesciences | $74.81
+1.2% | 11/11/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Edwards Lifesciences (NYSE:EW) on 11/11/2011 |
ADNT Adient | $16.85
-2.4% | 11/11/2011 | Initiated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Adient (NYSE:ADNT) on 11/11/2011 |
ALNY Alnylam Pharmaceuticals | $245.44
+2.8% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/10/2011 |
INTC Intel | $19.52
+2.4% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Intel (NASDAQ:INTC) on 11/10/2011 |
CRIS Curis | $3.08
+0.3% | 11/10/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $600.00 | N/A | View details for Rodman & Renshaw rating of Curis (NASDAQ:CRIS) on 11/10/2011 |
AAPL Apple | $254.49
+1.9% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | | N/A | View details for Rodman & Renshaw rating of Apple (NASDAQ:AAPL) on 11/9/2011 |
GERN Geron | $3.49
-4.6% | 11/9/2011 | Target Lowered by | Rodman & Renshaw | - | | $4.00 | N/A | View details for Rodman & Renshaw rating of Geron (NASDAQ:GERN) on 11/9/2011 |
BMY Bristol-Myers Squibb | $57.33
+1.8% | 11/9/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $52.50 | N/A | View details for Rodman & Renshaw rating of Bristol-Myers Squibb (NYSE:BMY) on 11/9/2011 |
USEG U.S. Energy | $1.55
+7.6% | 11/8/2011 | Reiterated by | Rodman & Renshaw | - | Outperform | $47.50 | N/A | View details for Rodman & Renshaw rating of U.S. Energy (NASDAQ:USEG) on 11/8/2011 |
ERII Energy Recovery | $15.14
-0.1% | 11/4/2011 | Reiterated by | Rodman & Renshaw | - | Market Perform | | N/A | View details for Rodman & Renshaw rating of Energy Recovery (NASDAQ:ERII) on 11/4/2011 |
